Chief Scientific Officer at Bicycle Therapeutics Limited to Provide Keynote Address at ADC Summit

LONDON - Feb. 20, 2015 - PRLog -- Recent clinical successes have generated intense interest in antibody-drug conjugates and they are now an increasingly active area of biopharma research, with developers and manufacturers investing towards this revolutionary therapeutic. To develop ADCs that are more specific, more stable, and more effective; continued optimisation of the antibody, linker and payload of an ADC is critical.

SMi is delighted to have Christophe Bonny, Chief Scientific Officer at Bicycle Therapeutics Limited giving a keynote address at its 4th annual ADC Summit 2015 conference, taking place on 18th - 19th May in London, UK

His timely presentation will focus on high affinity bicyclic peptides and their application to payload in oncology and he will explain how bicycles penetrate tumours rapidly, delivering high concentrations of payloads over hours, thus allowing efficient tumour killing while minimizing systemic toxin exposure. In addition to this, he will also discuss how scaffold-constrained bicyclic peptides show target-binding properties similar to antibodies but in a 100-fold smaller format.

This event will provide the opportunity to confer and debate how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.


Benefits of Attending:

• Hear more about the payload developments
• Receive updates on ADCs in clinical trials
• Learn more about biodistribution and tumour penetrations
• Aim for improvement of the therapeutic index
• Discover strategies for effective targeting ADC off-target toxicities
• Understand the status of the development of novel binding moieties

Expert Speakers Include:

• Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
• David Thurston, Professor of Drug Discovery, King's College London
• Angela Romanelli, Senior Director, Biomarkers, ImmunoGen, Inc.
• Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Limited
• Klaus Bosslet, Head Discovery Oncology, Pharma Research & Early Development, Roche Innovation Center Penzberg
• Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.
• Vijay Chudasama, Research Associate, University College London

To view the full programme visit http://www.smi-online.co.uk/2015conjugates48.asp

In addition to the event, there will be an interactive half day post-conference workshop taking place on the 20th May entitled: ADCs: A Journey Through Development.
Workshop Leaders: Dr. Richard Turner, Principle Consultant, Natalie Thomas, Consultant and Simon Bishop, Associate Consultant from BioDesk

For those who are interested in attending, there is currently a £300 discount available which expires on 27th February.

For more information or to register visit http://www.smi-online.co.uk/2015conjugates48.asp
Alternatively contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk

-------------------------- END --------------------------

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk